Stifel Nicolaus Issues Pessimistic Forecast for Inventiva (NASDAQ:IVA) Stock Price

Inventiva (NASDAQ:IVA) had its price target decreased by Stifel Nicolaus from $20.00 to $17.00 in a report issued on Friday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Several other equities analysts have also commented on the stock. UBS Group assumed coverage on shares of Inventiva in a research note on Tuesday, November 12th. They issued a “neutral” rating and a $3.00 price target on the stock. HC Wainwright lowered their target price on shares of Inventiva from $14.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, October 15th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Inventiva currently has an average rating of “Moderate Buy” and a consensus price target of $13.25.

Inventiva Trading Down 1.5 %

IVA opened at $2.62 on Friday. Inventiva has a one year low of $1.53 and a one year high of $4.75. The business’s 50-day simple moving average is $2.37 and its 200-day simple moving average is $2.64.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC acquired a new stake in Inventiva S.A. (NASDAQ:IVA) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,490 shares of the company’s stock, valued at approximately $38,000. 19.06% of the stock is owned by institutional investors.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.